fecal microbiota transplant fmt also known stool process transferring fecal bacteria microbes healthy individual another individual fmt effective treatment clostridioides difficile infection recurrent cdi fmt effective vancomycin alone may improve outcome first index infection side effects may include risk infections therefore donor cdi becoming common fmt gaining increasing prominence experts calling become firstline therapy fmt used experimentally treat gastrointestinal diseases including colitis constipation irritable bowel syndrome neurological conditions multiple sclerosis united states human feces regulated experimental drug since united kingdom fmt regulation remit medicines healthcare products regulatory fecal microbiota transplant approximately effective people cdi antibiotics worked disease recurs following people cdi recover one fmt study found fecal microbiota transplant effective simple procedure costeffective continued antibiotic administration reduced incidence antibiotic considered last resort therapy medical professionals due unusual nature invasiveness compared antibiotics perceived potential risk infection transmission lack medicare coverage donor stool position statements specialists infectious diseases moving toward acceptance fmt standard therapy relapsing cdi also medicare coverage united recommended endoscopic fmt elevated firstline treatment people deterioration severe relapsing c difficile fecal microbiota live rebyota approved medical use united states november fecal microbiota spores live vowst approved medical use united states april first fecal microbiota product taken may australian professor thomas borody treated first ulcerative colitis patient using fmt led longstanding symptom following justin bennet published first case report documenting reversal bennets colitis using c difficile easily eradicated single fmt infusion generally appears case ulcerative colitis published experience ulcerative colitis treatment fmt largely shows multiple recurrent infusions required achieve prolonged remission clinical trials underway evaluate fmt immunotherapy donors promote therapeutic response immunotherapyrefractory linked serious studies treating autism spectrum disorder fecal microbiota transplants one study conducted shanghai earlier study led arizona state arizona treatment received united states patent researchers hope fda adverse effects poorly understood included bacterial blood infections fever sirslike syndrome exacerbation inflammatory bowel disease people also condition mild gi distress generally resolve soon procedure including flatulence diarrhea irregular bowel movements abdominal distensionbloating abdominal paintenderness constipation cramping also concerns may spread person died united states receiving fmt contained drugresistant bacteria another person received transplant also us food drug administration fda issued warning potentially lifethreatening consequences transplanting material improperly screened evidencebased consensus guidelines optimal administration fmt documents outline fmt procedure including preparation material donor selection screening fmt gut microbiota comprises microorganisms reside along gastrointestinal tract including commensal symbiotic pathogenic organisms fmt transfer fecal material containing bacteria natural antibacterials healthy individual diseased preparing procedure requires careful selection screening potential donor close relatives often chosen account ease however case treatment active c diff family members intimate contacts may prone carriers screening involves medical history questionnaires screening various chronic medical diseases eg irritable bowel diseases crohns disease gastrointestinal cancer laboratory testing pathogenic gastrointestinal infections eg cmv c diff salmonella giardia gi parasites laboratory standards agreed recommendations vary size sample prepared ranging grams ounces fecal material effective fresh stool used increase viability bacteria within samples prepared within sample diluted times volume sample either normal sterile locations mix sample solvent mortar others use concern blender use account introduction air may decrease well aerosolization feces contaminating preparation suspension strained filter transferred administration suspension used later frozen diluted used without loss efficacy compared fresh fecal transplant material prepared administered clinical environment ensure precautions made suspensions fecal material given nasogastric nasoduodenal tubes colonoscope retention one hypothesis behind fecal microbiota transplant rests concept bacterial interference ie using harmless bacteria displace pathogenic organisms competitive niche case cdi c difficile pathogen recently pilot study five patients sterile fecal filtrate demonstrated comparable efficacy conventional fmt treatment recurrent conclusion study soluble filtrate components bacteriophages metabolites andor bacterial components enzymes may key mediators fmts efficacy rather intact bacteria demonstrated shortchain fatty acid valerate restored human fecal samples cdi patients bioreactor model recurrent cdi fmt antibiotic cessation may key mediator fmts efficacy studies identified rapidonset wellmaintained changes gut bacteriophage profile successful fmt colonisation recipient donor therefore another key area interest contrast case conditions ulcerative colitis single culprit yet however analysis gut microbiome metabolome changes fmt treatment ulcerative colitis identified possible candidates first use donor feces therapeutic agent food poisoning diarrhea recorded handbook emergency medicine chinese man hong ge century twelve hundred years later ming dynasty physician li shizhen used yellow soup aka golden syrup contained fresh dry fermented stool treat abdominal yellow soup made fecal matter water drunk consumption fresh warm camel feces also recommended bedouins remedy bacterial dysentery efficacy probably attributable antimicrobial subtilisin produced bacillus subtilis anecdotally confirmed german soldiers afrika korps world war however story likely myth independent research able verify first use fmt western medicine published ben eiseman colleagues team surgeons colorado treated four critically ill people fulminant pseudomembranous colitis c difficile known cause using fecal enemas resulted rapid return two decades fmt provided treatment option centre digestive diseases five dock thomas borody modernday proponent fmt may group treated first ulcerative colitis patient using fmt resulted complete resolution signs symptoms long treated total patients constipation diarrhea abdominal pain ulcerative colitis crohns disease fmt fmt patients considered cured patients reduction stool transplants considered percent effective severe cases c difficile colonization antibiotics first randomized controlled trial c difficile infection published january study stopped early due effectiveness fmt patients achieving cure single infusion achieving cure second infusion since time various institutions offered fmt therapeutic option variety interest fmt grew measured number clinical trials scientific united states fda announced february would hold public meeting entitled fecal microbiota transplantation held may may fda also announced regulating human fecal material american gastroenterological association aga american college gastroenterology acg american society gastrointestinal endoscopy asge north american society pediatric gastroenterology hepatology nutrition naspghan sought clarification fda center biologics evaluation research cber stated fmt falls within definition biological product defined public health service act definition drug within meaning federal food drug cosmetic argued since fmt used prevent treat cure disease condition intended affect structure function body product use would require investigational new drug ind july fda issued enforcement policy guidance regarding ind requirement using fmt treat c difficile infection unresponsive standard therapies fr july march fda issued proposed update called draft guidance finalized intended supersede july enforcement policy fmt treat c difficile infections unresponsive standard therapies proposed interim discretionary enforcement period informed consent used mentioning investigational aspect risks stool donor known either person condition physician stool donor stool screened tested direction physician fr february doctors people want use fmt worried proposal finalized would shutter handful stool banks sprung using anonymous donors ship providers hundreds miles fmt recurrent c difficile infections done without mandatory donor stool screening whereas fmt indications performed without fda issued three safety alerts regarding transmission pathogens first safety alert issued june described transmission multidrug resistant organism donor stool resulted death one second safety alert issued march regarding fmt produced improperly tested donor stools stool bank resulted several people hospitalizations two safety alert late march due concerns transmission donor november fda approved specific c difficile fecal microbiota treatment brand name administered rectally april agency approved live spore capsule taken mouth brand name team researchers massachusetts institute technology founded openbiome first public stool bank united across europe numerous stool banks emerged serve increasing demand consensus rapports standard operation procedures still differ institutions netherlands published protocols managing denmark institutions manages fmt according european tissue cell previous terms procedure include fecal bacteriotherapy fecal transfusion fecal transplant stool transplant fecal enema human probiotic infusion hpi procedure involves complete restoration entire fecal microbiota single agent combination agents terms replaced term fecal microbiota cultured intestinal bacteria studied alternative fecal microbiota one example rectal bacteriotherapy rbt developed tvede helms containing individually cultured strains anaerobic aerobic bacteria originating healthy human research also done identify relevant microbes within fecal transplants could isolated manufactured via industrial fermentation standardized products would scalable would reduce risk infections unwanted microbes would improve scientific study approach since substance would administered elephants hippos koalas pandas born sterile intestines digest vegetation need bacteria obtain eating mothers feces practice termed coprophagia animals eat veterinary medicine fecal microbiota transplant known transfaunation used treat ruminating animals like cows sheep feeding rumen contents healthy animal another individual species order colonize gastrointestinal tract normal httpsenwikipediaorgwikifecalmicrobiotatransplant